Boron for Osteoporosis

Boron is a trace mineral found mostly in plant foods and often sold for bone health, but it is not a proven treatment for osteoporosis. No randomised trial has given boron to people with osteoporosis, and no study has measured fractures. The only placebo-controlled trial that measured bone mineral density (BMD) enrolled 28 young college women, and boron did not directly affect their BMD (Meacham 1994; NIH ODS).

The case for boron rests mainly on a 1987 metabolic-ward study in which 12 postmenopausal women took 3 mg/day after months on a low-boron diet; their urinary calcium and magnesium losses fell and their oestradiol and testosterone rose (Nielsen 1987). A second study using the same dose found no effect on minerals, sex hormones or bone turnover markers (Beattie 1993), and a third found boron reduced urinary calcium loss only when magnesium intake was low (Hunt 1997). Calcium, vitamin D, exercise and, where needed, prescribed medicine remain the evidence-based approach (NAMS 2021).

Boron may influence bone through calcium metabolism, steroid hormones and the activity of osteoblasts and osteoclasts (the cells that build and break down bone), but its biochemical role is poorly understood (NIH ODS; Hunt 2012). In animals, boron deficiency causes abnormal limb development and weaker bones, and supplementation improves some measures of bone strength (NIH ODS).

In the 1987 study, boron markedly raised blood oestradiol (the main oestrogen) and testosterone, and the effect seemed larger when magnesium intake was low (Nielsen 1987). That matters because oestrogen loss after menopause is the main driver of osteoporosis (NAMS 2021). A 2014 review argued that intakes under 1 mg/day blunt boron's benefits, and that diets rich in fruits, vegetables, nuts and pulses (legumes) prevent a low intake (Nielsen 2014).

Lower urinary calcium and higher hormone levels are laboratory markers, not stronger bones. In a second metabolic study, the same 3 mg/day dose changed neither minerals, sex hormones nor urinary crosslinks (markers of bone breakdown); the authors thought the low-boron diet itself had altered calcium absorption and may have hidden any effect (Beattie 1993).

The body also regulates boron tightly. In 11 women on a metabolic ward, a 9.0-fold increase in dietary boron raised plasma boron only 1.5-fold, and nearly all of it was excreted; boron lowered urinary calcium loss in women on the basal magnesium diet but raised it in women given magnesium supplements (Hunt 1997). Animal results showing stronger bones have not been matched by human trials.

The human bone studies used 3 mg/day of elemental boron, usually after weeks or months on a deliberately low-boron diet (Nielsen 1987; Beattie 1993; Hunt 1997), and the young-women trial used the same dose (NIH ODS). That is more than most people eat: median dietary boron in US adults is 0.87-1.35 mg/day (NIH ODS). Reviews that favour boron suggest 3 mg/day for bone (Rondanelli 2020; Pizzorno 2015), but no trial has shown that this dose protects bone in osteoporosis.

Supplement labels state elemental boron, and common products contain 0.15-6 mg; forms include sodium borate, boron citrate, boron glycinate and calcium fructoborate, with no data comparing how well they are absorbed (NIH ODS). Fruit, tubers and legumes contain the most boron, and in the US coffee, milk, apples, beans and potatoes supply the most because people eat a lot of them (NIH ODS).

Twelve postmenopausal women aged 48-82 ate a diet supplying about 0.25 mg boron a day for 119 days and then took 3 mg/day. Boron markedly reduced urinary calcium and magnesium excretion, more so in the seven women on a low-magnesium diet, and markedly raised serum oestradiol and testosterone (Nielsen 1987). The study had no placebo group and did not measure bone.

Two later controlled-diet studies did not confirm a simple benefit. After 3 weeks on a low-boron diet (0.33 mg/day), 3 weeks of a 3 mg/day supplement had no effect on minerals, steroids or bone turnover crosslinks (Beattie 1993). In 11 women followed for 167 days, boron reduced the share of dietary calcium lost in urine in women on the basal magnesium diet but increased it in women given 200 mg/day of magnesium (Hunt 1997). Two of these three studies came from the same research group.

In 17 female college athletes and 11 sedentary women, boron or placebo was given over a one-year study period. Boron lowered serum phosphorus and changed serum magnesium and urinary boron; bone mineral density rose slightly in the athletes and fell slightly in the sedentary women (Meacham 1994). NIH ODS notes the 3 mg/day supplement did not directly affect bone mineral density.

These were young women, not people with osteoporosis or postmenopausal bone loss, so the trial can neither confirm nor rule out a benefit in osteoporosis.

In a pilot study of 66 postmenopausal Jordanian women with osteoporosis, higher estimated boron intake correlated with higher bone mineral density (p < .05) (Rababah 2024). In 53 postmenopausal Turkish women, those drinking water with at least 1 mg/L boron had higher serum osteocalcin, a marker of bone formation (Boyacioglu 2018). But in 134 Korean women with an average age of 41, boron intake of about 0.93 mg/day showed no significant relation to spine or hip bone density (Kim 2008).

Studies like these cannot show that boron causes the difference: diets high in boron are also high in fruit, vegetables and other plant foods.

A 2020 narrative review of 11 human studies (7 of boron alone, 4 with other nutrients) concluded that 3 mg/day is useful to support bone health (Rondanelli 2020), and a 2015 review proposed 3 mg/day for people with or at risk of osteopenia or osteoporosis (Pizzorno 2015). Neither used systematic methods, and the trials they drew on were small and measured markers rather than fractures.

Other assessments are more cautious. A 2008 evidence review in the Journal of Dietary Supplements found a lack of systematic study of boron in humans and described the osteoporosis studies as preliminary but promising, calling for randomised trials (J Diet Suppl 2008). A 2026 critical review concluded that current human data are insufficient to justify boron supplementation (Melenikioti 2026), and NIH ODS says more research is needed.

Combination products do not settle the question. In an open trial of 334 postmenopausal women with osteopenia, two tablets a day supplying 500 mcg boron in total, with calcium, vitamin D3, magnesium, zinc, copper and manganese, raised lumbar spine BMD by 1.5% over 12 months, while calcium carbonate alone only preserved spine BMD. The design cannot separate boron from the other ingredients (Benevolenskaia 2004).

At 3 mg/day, boron is far below the US tolerable upper intake level of 20 mg/day for adults, which also applies in pregnancy and breastfeeding; that limit is based on reproductive and developmental effects in animals (NIH ODS). The European limit is lower, at 10 mg/day (Rondanelli 2020). In an 8-week trial in 60 adults with kidney stones, measured supplement doses of 10 mg/day as boric acid or boron citrate, equal to the EFSA limit and three times the dose studied for bone, produced no clinically relevant effects apart from higher urine phosphorus with boric acid (Vousoughi 2025).

Boron is excreted mainly in urine (NIH ODS), so people with kidney disease should not take it without medical advice. Because one study found it raised oestradiol and testosterone (Nielsen 1987), people with hormone-sensitive conditions or on hormone therapy should ask first, although a later study found no hormone change (Beattie 1993). Toxicity mostly follows swallowing household boric acid or borax, usually by children under 6, and causes nausea, vomiting, diarrhoea and rash, and at very high doses kidney injury and convulsions (NIH ODS). Upper limits for children are 3-17 mg/day depending on age, and infants should get boron only from breast milk, formula and food (NIH ODS).

NIH ODS lists no clinically relevant interactions between boron and medicines. The practical issues are counting boron across products, its possible effect on sex hormones (Nielsen 1987), and the magnesium-dependent effect on calcium loss seen in one metabolic study (Hunt 1997). If you take an osteoporosis medicine, follow its label on how to space it from supplements.